Patents by Inventor William BODMER
William BODMER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10791747Abstract: One or more embodiments of the disclosure relates a food processing machine utilizing components using a variety of servo motors. The combination of the servo motors provides for a food processing machine without the need for complex hydraulics or gearboxes such that durability and compactness can be realized.Type: GrantFiled: January 27, 2016Date of Patent: October 6, 2020Assignee: FORMER ASSOCIATES, LLCInventors: James Petrovic, William Bodmer
-
Publication number: 20160213010Abstract: One or more embodiments of the disclosure relates a food processing machine utilizing components using a variety of servo motors. The combination of the servo motors provides for a food processing machine without the need for complex hydraulics or gearboxes such that durability and compactness can be realized.Type: ApplicationFiled: January 27, 2016Publication date: July 28, 2016Applicant: FORMER ASSOCIATES, LLCInventors: James PETROVIC, William BODMER
-
Publication number: 20100303867Abstract: A method is provided for reducing an immune response to an allergen or antigenic determinant thereof in a mammal by administering a modulator of the Notch signalling pathway.Type: ApplicationFiled: April 23, 2010Publication date: December 2, 2010Inventors: MARK WILLIAM BODMER, EMMANUEL CYRILLE PASCAL BRIEND, BRIAN ROBERT CHAMPION, ANDREW CHRISTOPHER LENNARD, GRAHAME JAMES MCKENZIE, SILVIA RAGNO, TAMARA TUGAL, GEORGE ALBERT WARD, LESLEY LYNN YOUNG
-
Publication number: 20040213797Abstract: A conjugate having first and second sequence, wherein the first sequence includes a polypeptide which is capable of binding to a MHC class II molecule and a polypeptide comprising a modulator of the Notch signalling pathway.Type: ApplicationFiled: January 23, 2004Publication date: October 28, 2004Inventors: Mark William Bodmer, Brian Robert Champion, Grahame James McKenzie, Lucy Emma Nye
-
Patent number: 6734286Abstract: An effective anti-IL-5 recombinant antibody molecule comprising heavy and/or light chain antigen-binding residues from a donor antibody.Type: GrantFiled: May 15, 2001Date of Patent: May 11, 2004Assignee: Celltech R&D LimitedInventors: Mark William Bodmer, Diljeet Singh Athwal, John Spencer Emtage
-
Publication number: 20030199679Abstract: Recombinant, in particular humanised, e.g. humanised chimeric and CDR-grafted humanised, antibody molecules having specificity for human TNF&agr;, are provided for use in diagnosis and therapy. In particular the antibody molecules have antigen binding sites derived from murine monoclonal antibodies CB0006, CB0010, hTNF3 or 101.4. Preferred CDR-grafted humanised anti-hTNF&agr; antibodies comprise variable region domains comprising human acceptor framework and donor antigen binding regions and wherein the frameworks comprise donor residues at specific positions. The antibody molecules may be used for therapeutic treatment of human patients suffering from or at risk of disorders associated with undesirably high levels of TNF, in particular for treatment of immunoregulatory and inflammatory disorders or of septic, endotoxic or cardiovascular shock.Type: ApplicationFiled: April 22, 2003Publication date: October 23, 2003Inventors: John Robert Adair, Diljeet Singh Athwal, John Spencer Emtage, Mark William Bodmer
-
Publication number: 20020042089Abstract: An effective anti-IL-5 recombinant antibody molecule comprising heavy and/or light chain antigen-binding residues from a donor antibody.Type: ApplicationFiled: May 15, 2001Publication date: April 11, 2002Applicant: Celltech Therapeutics Limited.Inventors: Mark William Bodmer, Diljeet Singh Athwal, John Spencer Emtage
-
Patent number: 6316227Abstract: An effective anti-IL-5 recombinant antibody molecule comprising heavy and/or light chain antigen-binding residues from a donor antibody.Type: GrantFiled: July 2, 1999Date of Patent: November 13, 2001Assignee: Celltech Therapeutics LimitedInventors: Mark William Bodmer, Diljeet Singh Athwal, John Spencer Emtage
-
Patent number: 6315999Abstract: An antibody to tumor necrosis factor-&agr; (anti-TNF) and an antibody to bacterial lipopolysaccharide (anti-LPS) used together in a neutropenic rat model of sepsis are shown to enhance survival of the rats relative to either antibody used alone. Pharmaceutical products including each of the components are therefore of utility in therapy of sepsis. The anti-LPS antibody included may be specific for the O-specific clain of a particular bacterial lipopolysaccharide (serotype specific antibody) but preferably recognizes the core glycolipid of lipopolysaccharide.Type: GrantFiled: June 2, 1994Date of Patent: November 13, 2001Assignee: Solvay, S.A.Inventors: Jerald C. Sadoff, Steven Michael Opal, Alan S. Cross, Mark William Bodmer
-
Patent number: 6180377Abstract: The invention describes humanized antibodies having specificity for the epitope recognised by the murine monoclonal antibody L243. Also described are processes for preparing said antibodies and pharmaceutical compositions and medical uses of said antibodies.Type: GrantFiled: March 25, 1996Date of Patent: January 30, 2001Assignee: Celltech Therapeutics LimitedInventors: Susan Adrienne Morgan, John Spencer Emtage, Mark William Bodmer, Diljeet Singh Athwal
-
Patent number: 6013642Abstract: This invention relates to the use of stroid sulphate sulphatase inhibitors which prevent the normal physiological effect of DHEA or related steroids on inflammatory responses.Type: GrantFiled: April 14, 1997Date of Patent: January 11, 2000Inventors: Roland Foulkes, John Spencer Emtage, Mark William Bodmer, Martin Rae Wales, Graham Arthur William Rook
-
Patent number: 5998586Abstract: An effective anti-IL-5 recombinant antibody molecule comprising heavy and/or light chain antigen-binding residues from a donor antibody.Type: GrantFiled: June 6, 1995Date of Patent: December 7, 1999Assignee: Celltech Therapeutics, LimitedInventors: Mark William Bodmer, Diljeet Singh Athwal, John Spencer Emtage
-
Patent number: 5994510Abstract: Recombinant, in particular humanised, e.g. humanised chimeric and CDR-grafted humanised, antibody molecules having specificity for human TNF.alpha., are provided for use in diagnosis and therapy. In particular, the antibody molecules have antigen binding sites derived from murine monoclonal antibodies CB0006, CB0010, hTNF3 or 101.4. Preferred CDR-grafted humanised anti-hTNF.alpha. antibodies comprise variable region domains comprising human acceptor framework and donor antigen binding regions and wherein the frameworks comprise donor residues at specific positions. The antibody molecules may be used for therapeutic treatment of human patients suffering from or at risk of disorders associated with undesirably high levels of TNF, in particular for treatment of immunoregulatory and inflammatory disorders or of septic, endotoxic or cardiovascular shock.Type: GrantFiled: June 1, 1995Date of Patent: November 30, 1999Assignee: Celltech Therapeutics LimitedInventors: John Robert Adair, Diljeet Singh Athwal, John Spencer Emtage, Mark William Bodmer
-
Patent number: 5965405Abstract: Methods for preparing Fv fragments which lack linking polypeptides in eukaryotic cells are provided.Type: GrantFiled: December 13, 1993Date of Patent: October 12, 1999Assignee: Celltech LimitedInventors: Gregory Paul Winter, Lutz Riechmann, Geoffrey Thomas Yarranton, Mark William Bodmer, Raymond John Owens
-
Patent number: 5958413Abstract: A combined preparation for simultaneous combined, simultaneous separate, or sequential use in the therapy of prophylaxis of disorders associated with undesirable high levels of TNF, e.g. septic or endotoxic shock and immunoregulatory and inflammatory disorders, which comprises an antibody to TNF or a TNF binding fragment thereof and a xanthine derivative. Particular preferred xanthine derivatives are 3,7-dimethyl-1(5-oxo-hexyl)xanthine (known as Pentoxifylline or TRENTAL) and 1-(5-hydroxy-5-methylhexyl)-3-methylxanthine and similar compounds. The anti-TNF antibody or fragment is preferably monospecific especially a humanized recombinant antibody or fragment.Type: GrantFiled: November 10, 1997Date of Patent: September 28, 1999Assignees: Celltech Limited, Hoechst AktiengesellschaftInventors: Hiristo Anagnostopulos, Ulrich Gebert, Heinz Hanel, Michael Limbert, Mark William Bodmer, Gerald Anthony Higgs
-
Patent number: 5877293Abstract: The present invention provides humanized antibody molecules (HAMs) having specificity for carcinoembryonic antigen (CEA) and having an antigen binding site wherein at least one of the complementarity determining regions (CDRs) of the variable domains is derived from the mouse monoclonal antibody A5B7 (A5B7 MAB) and the remaining immunoglobulin-derived parts of the HAM are derived from a human immunoglobulin. The HAMs may be chimeric humanized antibodies or CDR-grafted humanized antibodies and are preferably produced by recombinant DNA techniques. The HAMs are useful for in vivo diagnosis and therapy.Type: GrantFiled: May 24, 1995Date of Patent: March 2, 1999Assignee: Celltech Therapeutics LimitedInventors: John Robert Adair, Mark William Bodmer, Andrew Mountain, Raymond John Owens
-
Patent number: 5677425Abstract: The present invention provides an altered antibody molecule (AAM) having a hinge region which has a different number of cysteine residues from that found in the hinge region normally associated with the CH1 domain of the antibody molecule and a process for producing the same using recombinant DNA technology.Type: GrantFiled: August 18, 1994Date of Patent: October 14, 1997Assignee: Celltech Therapeutics LimitedInventors: Mark William Bodmer, John Robert Adair, Nigel Richard Whittle
-
Patent number: RE39548Abstract: An effective anti-IL-5 recombinant antibody molecule comprising heavy and/or light chain antigen-binding residues from a donor antibody.Type: GrantFiled: December 7, 2001Date of Patent: April 3, 2007Assignee: Celltech R&D LimitedInventors: Mark William Bodmer, Diljeet Singh Athwal, John Spencer Emtage